Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T. Shimokawaji

P2.01-88 C-Reactive Protein (CRP) as a Predictive Marker for Survival in Patients With Advanced NSCLC Treated With First Line Pembrolizumab Monotherapy

Journal of Thoracic Oncology

English

Related publications

P2.01-48 Predictive Factors in NSCLC Patients With Stage IIIB/IV Treated With First Line Platinum-Doublet Chemotherapy

Journal of Thoracic Oncology

English

P2.01-61 Body Mass Index Over Time Is Associated With Overall Survival in Advanced NSCLC Patients Treated With Immunotherapy.

Journal of Thoracic Oncology

English

Predictive Factors Associated With Prolonged Survival in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated With Gefitinib

British Journal of Cancer

Cancer Research

Oncology

2007

English

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology

English

Clinical Observation of Gefitinib as a First-Line Therapy in Sixty-Eight Patients With Advanced NSCLC

English

P002 Surgical Resection Improves the Survival of NSCLC Patients With Pleural Metastasis Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology

English

P2.01-21 Antigen Cascade Triggering Correlates With Prolonged Survival in Advanced NSCLC Patients Undergone PD-1 Blockade With Nivolumab.

Journal of Thoracic Oncology

English

P1.15-30 Survival of Patients With Advanced NSCLC Treated With First-Generation EGFR-TKIs at a Cancer Hospital in Thailand, 2011-2016

Journal of Thoracic Oncology

English

P057 Pembrolizumab + Chemo vs Chemo Alone as First Line Treatment in PD-L1 Positive Advanced NSCLC: A Meta-Analysis

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T. Shimokawaji

P2.01-88 C-Reactive Protein (CRP) as a Predictive Marker for Survival in Patients With Advanced NSCLC Treated With First Line Pembrolizumab Monotherapy

Related publications

P2.01-48 Predictive Factors in NSCLC Patients With Stage IIIB/IV Treated With First Line Platinum-Doublet Chemotherapy

P2.01-61 Body Mass Index Over Time Is Associated With Overall Survival in Advanced NSCLC Patients Treated With Immunotherapy.

Predictive Factors Associated With Prolonged Survival in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated With Gefitinib

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

Clinical Observation of Gefitinib as a First-Line Therapy in Sixty-Eight Patients With Advanced NSCLC

P002 Surgical Resection Improves the Survival of NSCLC Patients With Pleural Metastasis Treated With First-Line EGFR-TKIs

P2.01-21 Antigen Cascade Triggering Correlates With Prolonged Survival in Advanced NSCLC Patients Undergone PD-1 Blockade With Nivolumab.

P1.15-30 Survival of Patients With Advanced NSCLC Treated With First-Generation EGFR-TKIs at a Cancer Hospital in Thailand, 2011-2016

P057 Pembrolizumab + Chemo vs Chemo Alone as First Line Treatment in PD-L1 Positive Advanced NSCLC: A Meta-Analysis